Revolution Medicines Stock – Key Insights to Know

By Tamara Parker • Thursday, October 09 10:07 • Permanent Link

Revolution Medicines logged a 0.5% change during today's morning session, and is now trading at a price of $48.05 per share. The S&P 500 index moved -0.0%. RVMD's trading volume is 70,313 compared to the stock's average volume of 1,961,898.

Revolution Medicines trades -36.33% away from its average analyst target price of $75.47 per share. The 17 analysts following the stock have set target prices ranging from $64.0 to $99.0, and on average have given Revolution Medicines a rating of buy.

Anyone interested in buying RVMD should be aware of the facts below:

Revolution Medicines has moved -3.4% over the last year, and the S&P 500 logged a change of 16.8%
Based on its trailing earnings per share of -4.52, Revolution Medicines has a trailing 12 month Price to Earnings (P/E) ratio of -10.6 while the S&P 500 average is 29.3
RVMD has a forward P/E ratio of -11.9 based on its forward 12 month price to earnings (EPS) of $-4.05 per share
Its Price to Book (P/B) ratio is 4.81 compared to its sector average of 3.19
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers.
Based in Redwood City, the company has 700 full time employees and a market cap of $8.98 Billion.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.